Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GYRE Gyre Therapeutics

盘后交易 04-01 19:36:27 EDT

7.23

+0.26

+3.73%

盘后7.23

+0.000.00%

16:04 EDT

最高7.27	最低7.06	成交量6.87万
今开7.06	昨收6.97	日振幅3.01%
总市值7.01亿	流通市值1.48亿	总股本9,696万
成交额49.56万	换手率0.33%	流通股本2,052万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":7.23,"timestamp":1775073600000,"preClose":6.97,"halted":0,"volume":68748,"hourTrading":{"tag":"盘后","latestPrice":7.23,"preClose":7.23,"latestTime":"16:04 EDT","volume":1723,"amount":12454.8392048,"timestamp":1775073888442,"change":0,"changeRate":0,"amplitude":0.004149},"delay":0,"changeRate":0.03730272596843625,"floatShares":20523000,"shares":96963600,"eps":0.022484,"marketStatus":"盘后交易","change":0.26,"latestTime":"04-01 19:36:27 EDT","open":7.06,"high":7.27,"low":7.06,"amount":495602.6311,"amplitude":0.030129,"askPrice":8.33,"askSize":30,"bidPrice":6.7,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.022484,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775088000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":6.97,"preHourTrading":{"tag":"盘前","latestPrice":7.11,"preClose":6.97,"latestTime":"08:31 EDT","volume":39,"amount":277.29,"timestamp":1775046682696,"change":0.14,"changeRate":0.020086,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.23,"preClose":7.23,"latestTime":"16:04 EDT","volume":1723,"amount":12454.8392048,"timestamp":1775073888442,"change":0,"changeRate":0,"amplitude":0.004149},"volumeRatio":0.621781,"impliedVol":0.2903,"impliedVolPercentile":0.0691},"requestUrl":"/m/hq/s/GYRE","defaultTab":"news","newsList":[{"id":"1112195728","title":"Gyre Therapeutics达成收购Cullgen协议，获取靶向蛋白质降解平台及研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1112195728","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112195728?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:01","pubTimestamp":1772456500,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics已正式签署协议，将全面收购生物科技公司Cullgen。此项交易的核心标的为Cullgen旗下创新的靶向蛋白质降解技术平台及其相关研发管线。通过本次收购，Gyre Therapeutics旨在强化其在肿瘤治疗领域的技术布局，拓展创新药物研发能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601387836","title":"Gyre Therapeutics, Inc.盘中异动 快速上涨9.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601387836?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:32","pubTimestamp":1767623538,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时32分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨9.77%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家商业阶段的制药公司，开发和商业化针对器官疾病的小分子抗炎和抗纤维化药物，特别关注器官纤维化。该公司的可报告部门是 Gyre Pharmaceuticals，该公司从在中国销售 艾思瑞和某些仿制药、Gyre 和其他部门获得最大收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223219a49f643c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223219a49f643c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","GYRE","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160636585","title":"Gyre Therapeutics与中国药监局就海通酮有条件上市路径及优先审评资格达成共识，新药上市申请前会议取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1160636585","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160636585?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:01","pubTimestamp":1767614508,"startTime":"0","endTime":"0","summary":"在近期举行的新药上市申请前沟通会议上，Gyre Therapeutics与中国国家药品监督管理局药品审评中心就海通酮的注册路径达成重要共识。根据会议结果，该药物已明确符合中国附条件批准上市的标准，并同时获得优先审评资格认定。Gyre Therapeutics表示，公司将严格遵循药监局要求，有序推进后续申报工作。此次 alignment 不仅体现了中国监管机构对创新药研发的支持力度，也展现出Gyre Therapeutics在全球肝病治疗领域的技术领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137762718","title":"Gyre Therapeutics：指引反映Etorel商业化进程慢于预期，因中国集中采购政策的不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1137762718","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137762718?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:09","pubTimestamp":1762513749,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics：指引反映Etorel商业化进程慢于预期，因中国集中采购政策的不确定性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118444603","title":"Gyre Therapeutics：预计将在2026年提交Hydronidone治疗与Mash相关的肝纤维化的美国IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1118444603","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118444603?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:07","pubTimestamp":1762513646,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics：预计将在2026年提交Hydronidone治疗与Mash相关的肝纤维化的美国IND申请","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128737109","title":"Gyre Therapeutics 发布2025年第三季度及至今财务业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1128737109","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128737109?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:03","pubTimestamp":1762513390,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics 发布2025年第三季度及至今财务业绩并提供业务更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123064053","title":"Gyre Therapeutics宣布完成针对尘肺病的Pirfenidone胶囊三期临床试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1123064053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123064053?lang=zh_cn&edition=full","pubTime":"2025-10-15 19:00","pubTimestamp":1760526008,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics宣布完成针对尘肺病的Pirfenidone胶囊三期临床试验患者招募。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518278808","title":"Gyre Therapeutics, Inc.盘中异动 快速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278808?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:44","pubTimestamp":1741614262,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时44分，Gyre Therapeutics, Inc.股票出现波动，股价快速跳水5.04%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.74%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214423abf30134&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214423abf30134&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516367029","title":"Gyre Therapeutics, Inc.盘中异动 早盘快速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516367029","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516367029?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:49","pubTimestamp":1741099741,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时49分，Gyre Therapeutics, Inc.股票出现异动，股价大幅跳水5.03%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224901abe7f54c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224901abe7f54c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516652358","title":"Gyre Therapeutics, Inc.盘中异动 股价大跌5.30%报10.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516652358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516652358?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:33","pubTimestamp":1741026798,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时33分，Gyre Therapeutics, Inc.股票出现异动，股价急速下挫5.30%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304023318abe6790c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304023318abe6790c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167510703","title":"异动解读 | Gyre Therapeutics盘中大涨8.53% 疗效数据或成利好驱动因素","url":"https://stock-news.laohu8.com/highlight/detail?id=1167510703","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167510703?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:47","pubTimestamp":1740494854,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics今日盘中大涨8.53%,引发市场关注。这家生物制药公司主攻治疗肝纤维化相关药物研发,近期可能有利好推动股价上涨。Gyre Therapeutics目前正在研发一种治疗多种慢性肝病肝纤维化的药物 Hydronidone。市场对该药物疗效数据充满期待,有助于推升公司股价。除了 Hydronidone 外,Gyre Therapeutics在中国地区还有多个在研管线药物,包括吡非尼酮、F573、F528 和 F230 等。丰富的产品管线有望为公司带来长期的增长动力。投资者对该公司长期发展前景抱有信心,股价自然受到提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Gyre Therapeutics盘中大涨8.53% 疗效数据或成利好驱动因素","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090616","title":"Gyre Therapeutics, Inc.盘中异动 早盘急速上涨5.50%报11.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090616","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090616?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:32","pubTimestamp":1740493923,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时32分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨5.50%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223203a25386e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223203a25386e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514477545","title":"Gyre Therapeutics, Inc.盘中异动 早盘急速跳水5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514477545","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514477545?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:11","pubTimestamp":1740413509,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时11分，Gyre Therapeutics, Inc.股票出现异动，股价快速下跌5.37%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225001149abdb254f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225001149abdb254f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513215200","title":"Gyre Therapeutics, Inc.盘中异动 下午盘股价大跌5.02%报11.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513215200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513215200?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:15","pubTimestamp":1740161710,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时15分，Gyre Therapeutics, Inc.股票出现异动，股价大幅下跌5.02%。截至发稿，该股报11.93美元/股，成交量3.3733万股，换手率0.04%，振幅6.21%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222021511abd7df24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222021511abd7df24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512238166","title":"Gyre Therapeutics, Inc.盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512238166","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512238166?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:34","pubTimestamp":1739889246,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时34分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨5.59%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223406962797aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223406962797aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509177814","title":"Gyre Therapeutics, Inc.盘中异动 下午盘急速下挫5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509177814","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509177814?lang=zh_cn&edition=full","pubTime":"2025-02-08 02:58","pubTimestamp":1738954723,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日02时58分，Gyre Therapeutics, Inc.股票出现异动，股价急速跳水5.25%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208025843987dda7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208025843987dda7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509237702","title":"Gyre Therapeutics, Inc.盘中异动 下午盘急速上涨5.22%报12.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509237702?lang=zh_cn&edition=full","pubTime":"2025-02-06 02:36","pubTimestamp":1738780597,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日02时36分，Gyre Therapeutics, Inc.股票出现波动，股价快速拉升5.22%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.23%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206023639987ba2b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206023639987ba2b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506894933","title":"Gyre Therapeutics, Inc.盘中异动 快速上涨5.05%报11.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506894933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506894933?lang=zh_cn&edition=full","pubTime":"2025-01-25 02:32","pubTimestamp":1737743526,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日02时32分，Gyre Therapeutics, Inc.股票出现波动，股价快速上涨5.05%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125023206a22e8d62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125023206a22e8d62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503774571","title":"Gyre Therapeutics, Inc.盘中异动 早盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503774571","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503774571?lang=zh_cn&edition=full","pubTime":"2025-01-14 22:41","pubTimestamp":1736865717,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日22时41分，Gyre Therapeutics, Inc.股票出现异动，股价快速上涨5.11%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224158abaaaf5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224158abaaaf5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502864743","title":"Gyre Therapeutics, Inc.盘中异动 急速上涨6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502864743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502864743?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:32","pubTimestamp":1736519528,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时32分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨6.97%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。其相关个股中，Precision Biosciences, Inc.、Conduit Pharmaceuticals Inc.、Zyversa Therapeutics, Inc.涨幅较大，Zyversa Therapeutics, Inc.、Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.较为活跃，换手率分别为901.72%、131.67%、105.87%，振幅较大的相关个股有Zyversa Therapeutics, Inc.、Precision Biosciences, Inc.、Conduit Pharmaceuticals Inc.，振幅分别为15.25%、10.00%、8.90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102232089861e7b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102232089861e7b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","GYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gyretx.com","stockEarnings":[{"period":"1week","weight":0.0043},{"period":"1month","weight":-0.1541},{"period":"3month","weight":-0.0127},{"period":"6month","weight":-0.0731},{"period":"1year","weight":-0.0972},{"period":"ytd","weight":-0.0127}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.052},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0282},{"period":"1year","weight":0.1626},{"period":"ytd","weight":-0.0463}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Gyre Therapeutics, Inc.在特拉华州注册成立。该公司及其子公司是一家生物制药公司，专注于开发和治疗器官纤维化及炎症性疾病的小分子疗法。通过成功研发并推出治疗肺纤维化的产品艾思瑞（吡非尼酮），公司在华建立了坚实的商业基础，并成为肺纤维化治疗领域的知名参与者。通过向美国拓展，公司正推进包括用于肝纤维化的F351（羟尼酮）在内的在研产品管线。其战略核心是利用已上市产品支持后期开发，应对纤维化及相关炎症性疾病中未被满足的医疗需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.0674},{"month":2,"riseRate":0.545455,"avgChangeRate":0.018198},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.092501},{"month":4,"riseRate":0.5,"avgChangeRate":-0.01248},{"month":5,"riseRate":0.4,"avgChangeRate":0.107158},{"month":6,"riseRate":0.4,"avgChangeRate":0.010302},{"month":7,"riseRate":0.3,"avgChangeRate":-0.013004},{"month":8,"riseRate":0.6,"avgChangeRate":0.030061},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.147023},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.037523},{"month":11,"riseRate":0.545455,"avgChangeRate":0.207378},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054047}],"exchange":"NASDAQ","name":"Gyre Therapeutics","nameEN":"Gyre Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Gyre Therapeutics(GYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Gyre Therapeutics,GYRE,Gyre Therapeutics股票,Gyre Therapeutics股票老虎,Gyre Therapeutics股票老虎国际,Gyre Therapeutics行情,Gyre Therapeutics股票行情,Gyre Therapeutics股价,Gyre Therapeutics股市,Gyre Therapeutics股票价格,Gyre Therapeutics股票交易,Gyre Therapeutics股票购买,Gyre Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Gyre Therapeutics(GYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}